Adagene's ADG126 to be Highlighted in Two Presentations at the 2025 Chinese Society of Clinical Oncology (CSCO) Meeting in Jinan, China
1. ADG126 will be presented at the CSCO Meeting on September 11. 2. Updated data shows ADG126 has ~30% objective response rate in MSS CRC. 3. The treatment has a favorable safety profile with less than 20% Grade 3 TRAEs. 4. Median overall survival of 19.4 months observed in certain patient cohorts. 5. ADG126 targets cold tumors, enhancing treatment for difficult-to-treat MSS CRC cases.